Kolexia
Delfau-Larue Marie-Helene Biologie médicale
Delfau-Larue Marie-Helene
Biologie médicale
Hôpital Henri Mondor
Créteil, France
167 Activités
550 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome T Lymphome à cellules du manteau Lymphome B Lymphome folliculaire Tumeurs cutanées Lymphome T périphérique Maladie résiduelle Lymphadénopathie angio-immunoblastique

Collaborateurs

Voir plus
Haioun Corinne
Haioun Corinne
Hôpital Henri Mondor, Créteil, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Gaulard Philippe
Gaulard Philippe
Hôpital Henri Mondor, Créteil, France
Thieblemont Catherine
Thieblemont Catherine
Hôpital Saint-Louis, Paris, France

Industries

Voir plus
Amgen
7 collaboration(s)
Dernière en 2022
Gilead
7 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
4 collaboration(s)
Dernière en 2022
Janssen
4 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   16 février 2024
Le récepteur type 2 du facteur de nécrose tumorale pourrait représenter une cible thérapeutique alternative au cours du syndrome de Sézary et du mycosis fongoïde
Journées dermatologiques de Paris 2023   01 décembre 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   22 novembre 2023
Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?
Histopathology   21 novembre 2023
Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL
65th ASH Annual Meeting Abstracts   02 novembre 2023
Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa
65th ASH Annual Meeting Abstracts   02 novembre 2023
Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network
65th ASH Annual Meeting Abstracts   02 novembre 2023